Doximity, 10x Genomics and Omnicell stand out in the Medical Info Systems sector, leveraging AI, telehealth, and workflow ...
Omnicell , Inc. (NASDAQ:OMCL), a leading provider of medication management solutions in the healthcare technology sector, has been navigating a complex market environment characterized by both ...
Company Establishes New Hub Dedicated to Addressing Challenges Across the Medication Journey As hospitals and health systems are grappling with rising costs and staffing shortages, we believe that ...
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ: OMCL) (“Omnicell”) today announced that it intends to offer, subject to market conditions and other factors, $150.0 million aggregate ...
Results exceed previously issued second quarter 2025 guidance for revenues, non-GAAP EBITDA and non-GAAP EPS Raises full year 2025 total revenues, non-GAAP EBITDA and non-GAAP EPS guidance FORT WORTH, ...
Omnicell (NASDAQ:OMCL – Get Free Report) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Monday. Several other brokerages have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback